Click Therapeutics said today that it landed a $17 million round, led by Sanofi‘s (NYSE:SNY) venture arm, to fund its platform of prescription digital therapeutics.
The company’s commercial product, Clickotine, is designed to help people quit smoking. The digital smoking cessation program uses a personalized plan to help people overcome tobacco cravings, adhere to medication regimens and connect with people in a support network.
Get the full story at our sister site, Drug Delivery Business News.